Patent ID: 8735079

Claim:
A method for assessing the risk of future cardiovascular events in an individual with stable coronary artery disease (CAD), the method comprising: (a) contacting a blood, plasma, or serum sample from the individual with antibodies of a dual antibody assay for the determination of procalcitonin (PCT) with a functional assay sensitivity of <0.007 ng/ml PCT to determine the level of PCT in said blood, plasma or serum sample from the individual; (b) determining the level of at least one further analyte useful for cardiovascular prognosis, said analyte being selected from GDF-15, cystatin-C and their precursors; and (c) identifying the individual as being at highest risk of experiencing future adverse cardiovascular events when the PCT level is equal to or greater than 0.05 ng/ml and the level of the further analyte is elevated when compared to levels in healthy individuals.